Glow-in-the-Dark dye could help surgeons spot hidden cancer cells
NCT ID NCT07460765
First seen Apr 07, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This early-stage trial tests a fluorescent dye attached to the cancer drug nivolumab. The dye is meant to make cancer cells glow during surgery, helping surgeons remove them more precisely. The study will enroll 40 people with head and neck cancer who are already scheduled for surgery. The main goal is to check if the dye is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab with a fluorescent dye (IRDye800CW)
What this could lead to
If successful, this could help surgeons see cancer cells more clearly during surgery, potentially leading to more complete tumor removal.
What could go wrong
This is a very early phase 1 safety study with only 40 people. The dye may not work as hoped, and there could be side effects from the drug or the dye.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.